February 16-18, 2020

Hard Rock Guitar Hotel & Casino in Hollywood, Florida

Noble Capital Markets' 16th annual emerging growth investor conference provides a forum where private and publicly traded emerging growth companies with less than $2 billion in market capitalization can connect with the investment community, fund managers and high-net-worth investors who focus on small and microcap equities. Taking place at the guitar-shaped Hard Rock Hotel & Casino in Hollywood, Fla., the two-day conference broadens access to investors worldwide by also hosting the conference on NobleCon16 will include presentations by approximately 125 public companies, expert panels moderated by industry leaders, and the opportunity for investors to meet and network with management of presenting companies on a one-on-one basis. Among the lineup of world-class keynote speakers scheduled for this year's conference are Jeb Bush, the 43rd governor of the state of Florida, and Ari Fleisher, White House press secretary for former President George W. Bush. NobleCon16 also provides networking opportunities through social activities and special events. For more information visit

Conference Dates: February 17 February 18


Seanergy Maritime Holdings Corp. (NASDAQ: SHIP)

Seanergy Maritime Holdings (NASDAQ: SHIP) is the only pure-play Capesize ship-owner publicly listed in the United States. Seanergy provides marine dry bulk transportation services through a modern fleet of 10 Capesize vessels, with a cargo-carrying capacity of approximately 1,748,581 dwt and an average fleet age of about 10.6 years. The company is incorporated in the Marshall Islands with executive offices in Athens, Greece and an office in Hong Kong. For more information, visit the company's website at

Veritas Farms Inc. (OTCQB: VFRM)

Veritas Farms (OTCQB: VFRM) is a vertically integrated agribusiness focused on producing superior quality, whole plant, full spectrum hemp oils and extracts containing naturally occurring cannabinoids. Veritas currently owns and operates a 140-acre farm and production facilities in Pueblo, Colorado, and is registered with the Colorado Department of Agriculture to grow industrial hemp. The company markets and sells products under its Veritas Farms™ brand and manufactures private label products for a number of leading distributors and retailers. Veritas Farms™ brand full spectrum hemp oil products include vegan capsules, tinctures, formulations for sublingual applications and infused edibles, lotions, salves, and oral syringes in a variety of size formats and flavors. All Veritas Farms™ brand products are third-party laboratory tested for strength and purity. For more information, visit the company's website at


Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue™ Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. Imagin Medical's initial focus is bladder cancer. For more information, visit the company's website at

Golden Valley Mines Ltd. (TSXV: GZZ)

Golden Valley Mines (TSXV: GZZ) is focused on project generation and continues to evaluate opportunities to enhance its mining exploration property portfolio. The company is able to grow its current assets by way of partner-funded option/joint ventures and through its shareholdings in related entities. Golden Valley Mines holds approximate interests in each of Abitibi Royalties Inc. (44%), Val-D'Or Mining Corporation (37%) and International Prospect Ventures Ltd. (16%). For more information, visit the company's website at

Onconova Therapeutics Inc. (NASDAQ: ONTX)

Onconova Therapeutics (NASDAQ: ONTX) is a phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. Advanced clinical trials with the company's lead compound, rigosertib, are aimed at what the company believes are unmet medical needs of patients with MDS. Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300. For more information, visit the company's website at


Great Panther Mining Ltd. (TSX: GPR) (NYSE: GPL)

Great Panther Mining (TSX: GPR) (NYSE: GPL) is an intermediate gold and silver mining and exploration company operating three mines: the Tucano Gold Mine in Amapá State, Brazil; and two primary silver mines in Mexico: the Guanajuato Mine Complex and the Topia Mine. Great Panther also owns the Coricancha Mine Complex in Peru and has executed a successful 2019 bulk sample mining program in accordance with the May 2018 PEA. For more information, visit the company's website at

ACCO Brands Corp. (NYSE: ACCO)

ACCO Brands (NYSE: ACCO) is one of the world's largest designers, marketers and manufacturers of branded academic, consumer and business products. The company's widely recognized brands include Artline®, AT-A-GLANCE®, Barrilito®, Derwent®, Esselte®, Five Star®, Foroni®, GBC®, Hilroy®, Kensington®, Leitz®, Mead®, Quartet®, Rapid®, Rexel®, Swingline®, Tilibra®, Wilson Jones® and many others. ACCO Brands sells its products in more than 100 countries around the world. For more information, visit the company's website at


Aeterna Zentaris Inc. (TSX: AEZS) (NYSE: AEZS)

Aeterna Zentaris (NASDAQ: AEZS) (TSX: AEZS) is a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, principally through out-licensing arrangements. Aeterna Zentaris is the licensor and party to a license and assignment agreement with Novo Nordisk A/S to carry out joint development, manufacturing, registration, regulatory, and supply chain for the commercialization of Macrilen™ (macimorelin), for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada. The clinical development of Macrilen™ for pediatric use is ongoing. Aeterna Zentaris is actively pursuing business development opportunities for Macrilen™ in the rest of the world and to monetize the value of its non-strategic assets. For more information, visit the company's website at

Indonesia Energy Corporation Ltd. (NYSE: INDO)

Indonesia Energy (NYSE: INDO) is engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. The company's strategy is to build an oil and gas assets portfolio with an optimum mix between medium-sized producing blocks and exploration blocks with significant potential resources. IEC's principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (1,000,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California. For more information, visit the company's website at

Applied Energetics Inc. (OTCQB: AERG)

Applied Energetics (OTCQB: AERG) ("AE") specializes in the development and manufacture of advanced high-performance lasers, high voltage electronics, advanced optical systems, and integrated guided energy systems for defense, aerospace, industrial and scientific customers worldwide. AE has pioneered and holds all crucial intellectual property rights to the development and use of Laser Guided Energy (LGETM) technology and related solutions for commercial, defense and security applications, protected by 26 patents and 11 additional Government Sensitive Patent Applications "GSPA." The company's 11 GSPA's are held under secrecy orders of the U.S. government and allow AE greatly extended protection rights. For more information, visit the company's website at


Trovagene Inc. (NASDAQ: TROV)

Trovagene (NASDAQ: TROV) is a clinical-stage Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including solid tumors, leukemias and lymphomas. Trovagene has intellectual property and proprietary technology that enables the company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics. For more information, visit the company's website at

ISG (Information Services Group) (NASDAQ: III)

ISG (Information Services Group) (NASDAQ: III) is a leading global technology research and advisory firm with more than 700 clients, including more than 70 of the Top 100 enterprises in the world. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry's most comprehensive marketplace data. For more information, visit the company's website at

Ely Gold Royalties Inc. (TSXV: ELY) (OTCQB: ELYGF)

Ely Gold Royalties Inc. (TSXV: ELY) (OTCQB: ELYGF) is an emerging royalty company with development assets focused in Nevada and Quebec. Its current portfolio includes 35 deeded royalties and 21 properties optioned to third parties. Ely Gold's royalty portfolio includes producing royalties, fully permitted mines and development projects that are at or near producing mines. The company is actively seeking opportunities to purchase existing third-party royalties for its portfolio and all the company's option properties are expected to produce royalties, if exercised. The royalty and option portfolios are currently generating significant revenue. Ely Gold is well positioned with its current portfolio of over 20 available properties to generate additional operating revenue through option and sale agreements. The company has a proven track record of maximizing the value of its properties through claim consolidation and advancement using its extensive, proprietary data base. All portfolio properties are sold or optioned on a 100% basis, while the company retains royalty interests. For more information, visit the company's website at

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI)

BrainStorm Cell Therapeutics (NASDAQ: BCLI) is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The company holds the rights to clinical development and commercialization of the NurOwn® Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) for ALS. Brainstorm has fully enrolled the phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. In December 2018, Brainstorm received U.S. FDA clearance to initiate a phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in progressive multiple sclerosis (NCT03799718) and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website at


Matinas BioPharma Inc. (NYSE: MTNB)

Matinas BioPharma (NYSE: MTNB) is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Matinas BioPharma is also developing MAT2203, an oral, encochleated formulation of amphotericin B, to treat serious invasive fungal infections. The drug is based on the company's proprietary lipid nano-crystal (LNC) platform technology which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable. For more information, visit the company's website at

International Seaways Inc. (NYSE: INSW)

International Seaways (NYSE: INSW) is one of the largest tanker companies worldwide providing energy transportation services for crude oil and petroleum products in International Flag markets. International Seaways owns and operates a fleet of 42 vessels, including 13 VLCCs, two Suezmaxes, six Aframaxes/LR2s, 12 Panamaxes/LR1s and seven MR tankers. Through joint ventures, International Seaways currently has ownership interests in two floating storage and offloading service vessels. The company has an experienced team committed to the highest operating practices and the highest levels of customer service and operational efficiency. For more information, visit the company's website at

Educational Development Corp. (NASDAQ: EDUC)

Educational Development (NASDAQ: EDUC) ("EDC") is a publishing company specializing in books for children. EDC is the exclusive United States trade co-publisher of the line of educational children's books produced in the United Kingdom by Usborne Publishing Limited, and also exclusively publishes books through its ownership of Kane Miller Book Publisher – both of which are international award-winning publishers of children's books. EDC's current catalog contains over 2,000 titles, with new additions semi-annually. Both Usborne and Kane Miller products are sold via 4,000 retail outlets and by independent consultants, who hold book showings in individual homes, through social media, book fairs with school and public libraries, direct and internet sales. For more information, visit the company's website at

EuroDry Ltd. (NASDAQ: EDRY)

EuroDry (NASDAQ: EDRY) operates in the dry cargo, drybulk shipping market. Company operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004-certified affiliated ship management company and Eurobulk (Far East) Ltd. Inc., which are responsible for the day-to-day commercial and technical management and operations of the vessels. EuroDry employs its vessels on spot and period charters. The company has a fleet of seven vessels, including four Panamax drybulk carriers, one Ultramax drybulk carrier and two Kamsarmax drybulk carriers. EuroDry's seven drybulk carriers have a total cargo capacity of 528,931 dwt. For more information, visit the company's website at


ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF)

ProMIS Neurosciences (TSX: PMN) (OTCQB: ARFXF) is a development-stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. For more information, visit the company's website at


SRAX (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX's technology unlocks data to reveal brands' core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through the BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data thereby offering everyone in the Internet ecosystem choice, transparency and compensation. SRAX's tools deliver a digital competitive advantage for brands in the CPG, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company's website at

Euroseas Ltd. (NASDAQ: ESEA)

Euroseas (NASDAQ: ESEA) was formed in May 2005 to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas operates in the container shipping market. The company's operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements. The company has a fleet of 19 vessels, including 14 feeder containerships and five intermediate container carriers. Euroseas 19 containerships have a cargo capacity of 51,083 teu. For more information, visit the company's website at


Genprex Inc. (NASDAQ: GNPX)

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform. The company's lead product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company's website at

Tribune Publishing Company (NASDAQ: TPCO)

Tribune Publishing (NASDAQ: TPCO) is a media company rooted in award-winning journalism. Headquartered in Chicago, Tribune Publishing operates local media businesses including the Chicago Tribune, New York Daily News, The Baltimore Sun, Orlando Sentinel, South Florida's Sun-Sentinel, Virginia's Daily Press and The Virginian-Pilot, The Morning Call of Lehigh Valley, Pennsylvania and the Hartford Courant. In addition to award-winning local media businesses, Tribune Publishing operates national and international brands such as Tribune Content Agency and The Daily Meal and is the majority owner of the product review website BestReviews. Tribune Publishing creates and distributes content across its media portfolio, offering integrated marketing, media, and business services to consumers and advertisers, including digital solutions and advertising opportunities. For more information, visit the company's website at


electroCore Inc. (NASDAQ: ECOR)

electroCore (NASDAQ: ECOR) is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company's initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache. electroCore was founded in 2005 on a unified belief that neuromodulation could be used in novel ways to help patients break free from treatments they aren't happy with. For more information, visit the company's website at

Eagle Bulk Shipping Inc. (NASDAQ: EGLE)

Eagle Bulk Shipping (NASDAQ: EGLE) is a U.S.-based fully integrated shipowner-operator providing global transportation solutions to a diverse group of customers, including miners, producers, traders and end users. Headquartered in Stamford, Connecticut, with offices in Singapore and Copenhagen, Eagle focuses exclusively on the versatile mid-size drybulk vessel segment and owns one of the largest fleets of Supramax / Ultramax vessels in the world. The company performs all management services in-house (including strategic, commercial, operational, technical and administrative) and employs an active management approach to fleet trading with the objective of optimizing revenue performance and maximizing earnings on a risk-managed basis. For more information, visit the company's website at


Dyadic International Inc. (NASDAQ: DYAI)

Dyadic International (NASDAQ: DYAI) is a global biotechnology company developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products. For more information, visit the company's website at


1-800-FLOWERS.COM (NASDAQ: FLWS) is a leading provider of gifts designed to help customers express, connect and celebrate. The company's Celebrations Ecosystem includes:®,®, Cheryl's Cookies®, Harry & David ®, Shari's Berries®,®, Moose Munch®, The Popcorn Factory®, Wolferman's Bakery℠, Personalization Universe®, Simply Chocolate®, Goodsey® and Stock Yards®. The company also operates BloomNet®, an international floral wire service providing a broad-range of products and services designed to help professional florists grow their businesses profitably; Napco℠, a resource for floral gifts and seasonal décor; and DesignPac Gifts, LLC, a manufacturer of gift baskets and towers. FLWS was recognized as the 2019 Mid-Market Company of the Year by CEO Connection. For more information, visit the company's website at

Freedom Holding Corp. (NASDAQ: FRHC)

Freedom Holding (NASDAQ: FRHC) is a financial services holding company conducting retail financial brokerage, investment counseling, securities trading, investment banking and underwriting services through its subsidiaries under the name of Freedom Finance in the Commonwealth of Independent States (CIS). The company is a professional participant of the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), the Saint-Petersburg Exchange (SPB) the Republican Stock Exchange of Tashkent (UZSE) and the Ukrainian Exchange. Freedom Holding is headquartered in Almaty, Kazakhstan, with executive office locations in Russia and the United States. The company operates branch offices in Kazakhstan, Russia, Kyrgyzstan, Ukraine, Germany and Cyprus. For more information, visit the company's website at


Helix BioPharma Corp. (TSX: HBP)

Helix BioPharma (TSX: HBP) is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor ("CAR")-based cell therapies. Helix is also developing a number of Tumor Attackers, CAR-T, that are potential treatment of hematological and solid tumors. For more information, visit the company's website at

Entravision Communications Corp. (NYSE: EVC)

Entravision (NYSE: EVC) is a diversified global media, advertising technology and data analytics company that reaches and engages Latino consumers primarily in the U.S., Mexico, Latin America and Spain. Entravision's portfolio includes digital media properties and advertising technology platforms that deliver performance-based solutions and data insights, 55 television stations, and 49 radio stations. Entravision is the largest affiliate group of both the Univision and UniMás television networks, and its Spanish-language radio stations feature its nationally recognized talent. Entravision also operates Entravision Solutions, a national sales and marketing organization representing over 300 owned and affiliated radio stations, radio networks and digital media platforms, and Headway's audio advertising platform, AudioEngage. For more information, visit the company's website at

Endeavour Silver Corp. (TSX: EDR) (NYSE: EXK)

Endeavour Silver (TSX: EDR) (NYSE: EXK) is a mid-tier precious metals mining company that owns and operates three high-grade, underground, silver-gold mines in Mexico. Endeavour is currently advancing the Terronera mine project toward a development decision and exploring its portfolio of exploration and development projects in Mexico and Chile to facilitate its goal to become a premier senior silver producer. The company's newest mine, El Compas in Zacatecas state, attained commercial production in Q1, 2019. For more information, visit the company's website at


Ceapro Inc. (TSXV: CZO)

Ceapro (TSXV: CZO) is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information, visit the company's website at

Interpace Biosciences Inc. (NASDAQ: IDXG)

Interpace Biosciences (NASDAQ: IDXG) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The company's Interpace Diagnostics subsidiary provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer. Its Interpace Pharma Solutions subsidiary provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Interpace has four commercialized molecular tests and one test in a clinical evaluation process: PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules; and RespriDX® that differentiates lung cancer of primary vs. metastatic origin. For more information, visit the company's website at

Qualstar Corp. (NASDAQ: QBAK)

Qualstar (NASDAQ: QBAK) is a diversified electronics manufacturer specializing in data storage. The company's data storage products are used to provide highly scalable and reliable solutions to store and retrieve very large quantities of electronic data. Qualstar's products are known throughout the world for their high quality and Simply Reliable™ designs that provide years of trouble-free service. Through a wholly owned subsidiary, Qualstar also provides high efficiency and high-density power supplies under the N2Power™ brand. The company's N2Power power supply products provide compact and efficient power conversion for a wide variety of industries and applications including but not limited to telecom, networking, broadcast, industrial, lighting, gaming and test equipment. For more information, visit the company's website at

Lumina Gold Corp. (TSXV: LUM) (OTCQX: LMGDF)

Lumina Gold (TSXV: LUM) (OTCQX: LMGDF) is a Vancouver, Canada-based precious and base metals exploration and development company focused on the Cangrejos Gold-Copper Project located in El Oro Province, southwest Ecuador. The company owns 100% of this 16.7 million ounce gold deposit, which also hosts 2.2 billion pounds of copper. The project is now the 38th largest primary gold deposit in the world. It has the benefit of being located 40 km from a commercial deep sea port and also has access to cheap hydro power for operations. Lumina has an experienced management team with a successful track record of advancing and monetizing exploration projects. For more information, visit the company's website at


Citius Pharmaceuticals Inc. (NASDAQ: CTXR)

Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, focusing on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients. The company seeks to achieve leading market positions by providing therapeutic products that address unmet medical needs, using previously approved drugs with substantial safety and efficacy data to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, visit the company's website at

One Stop Systems Inc. (NASDAQ: OSS)

One Stop Systems (NASDAQ: OSS) designs and manufactures innovative specialized high-performance computing building blocks and platforms for OEMs that provide edge systems to scientists, engineers, creators and other professionals for their mission critical applications. These specialized platforms include customized servers, compute accelerators, flash storage arrays, expansion systems and storage software used for deep learning, AI, defense, finance and entertainment applications. OSS utilizes the power of PCI Express, the latest GPU accelerators and NVMe flash cards to build award-winning systems, including many industry firsts, for OEMs and government customers. OSS products are available directly or through global distributors. For more information, visit the company's website at

Salem Media Group Inc. (NASDAQ: SALM)

Salem Media Group (NASDAQ: SALM) is America's leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day, Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. For more information, visit the company's website at

Silver One Resources Inc. (TSXV: SVE) (OTCQB: SLVRF) (FSE: BRK1)

Silver One Resources (TSXV: SVE) (OTCQB: SLVRF) (FSE: BRK1) is focused on the exploration and development of quality silver projects. The company holds an option to acquire a 100%-interest in its flagship project, the past-producing Candelaria Mine located in Nevada. Silver One is currently conducting metallurgical tests to determine the best methods for and potential recoveries of silver from the historic leach pads. Silver One has staked 636 lode claims and entered into a lease/purchase agreement to acquire five patented claims on its Cherokee project located in Lincoln County, Nevada, host to multiple silver-copper-gold vein systems, traced to date for over 16 km along-strike. In addition, the company also holds a 100% interest in three significant silver assets located in Mexico - Peñasco Quemado, Sonora; La Frazada, Nayarit; and Pluton, Durango. For more information, visit the company's website at


Kelly Services (NASDAQ: KELYA, KELYB)

Kelly Services® (NASDAQ: KELYA, KELYB) is a global workforce solution that offers schools unparalleled experience, value and expertise while carrying out the company's mission to provide end-to-end educational staffing solutions. Kelly Services is the parent company of Kelly Education, the first and largest provider of educational staffing in the United States. Kelly Education also provides assistance with the management and placement of non-educational staff such as office clerical, administrative, food service, janitors and school nurses. For more information, visit the company's website at

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF)

Exro Technologies (CSE: XRO) (OTCQB: EXROF) facilitates the transition to clean energy by providing products and services to manufacturers to increase the efficiency and reliability of power systems, including electric motors, generators and batteries. Exro's patented technology enhances energy systems by dynamically sensing and adapting variable inputs and optimally matching them to desired outputs, creating measurable performance gains and extended lifespan. The widespread applications of the technology apply to optimizing the performance of electric vehicles, UAVs, ship drives, pumps, industrial motors, and energy capture from wind and tides. For more information, visit the company's website at

Ocugen, Inc. (NASDAQ: OCGN)

Ocugen (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – "one to many". And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. For more information, visit the company's website at

SPI Energy Co. Ltd. (NASDAQ: SPI)

SPI Energy (NASDAQ: SPI) is a global provider of photovoltaic ("PV") solutions for business, residential, government and utility customers and investors. The company develops solar PV projects that are either sold to third-party operators or owned and operated by the company for selling of electricity to the grid in multiple countries in Asia, North America and Europe. SPI Energy's subsidiary in Australia primarily sells solar PV components to retail customers and solar project developers. SPI Energy is headquartered in Hong Kong. It has an operating office in Santa Clara, Calif., and maintains global operations in Asia, Europe, North America and Australia. For more information, visit the company's website at


Salarius Pharmaceuticals Inc. (NASDAQ: SLRX)

Salarius Pharmaceuticals (NASDAQ: SLRX) is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company's lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease Designation by the FDA. Salarius is also developing Seclidemstat for several cancers with high unmet medical need, with a second phase 1 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, visit the company's website at

Protalix BioTherapeutics Inc. (TASE: PLX) (NYSE: PLX)

Protalix BioTherapeutics (TASE: PLX) (NYSE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix's development pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets. For more information, visit the company's website at

Contact us: 212.418.1217